AR085580A1 - Formulaciones de otamixaban con estabilidad mejorada - Google Patents
Formulaciones de otamixaban con estabilidad mejoradaInfo
- Publication number
- AR085580A1 AR085580A1 ARP120101016A ARP120101016A AR085580A1 AR 085580 A1 AR085580 A1 AR 085580A1 AR P120101016 A ARP120101016 A AR P120101016A AR P120101016 A ARP120101016 A AR P120101016A AR 085580 A1 AR085580 A1 AR 085580A1
- Authority
- AR
- Argentina
- Prior art keywords
- acid
- pharmaceutical composition
- amino
- acids
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
Una composición farmacéutica que comprende (2R,3R)-2-{3-[amino(imino)metil]bencil}-3-{[4-(1-oxidopiridin-4-il)benzoil]amino}butanoato de metilo o una sal farmacéuticamente aceptable del mismo y un compuesto reactivo ácido farmacéuticamente aceptable, o a una solución o dispersión acuosa de la composición así como a un procedimiento para la preparación de la misma, a métodos para usar tales composiciones para tratar a sujetos que sufren enfermedades que se pueden mejorar por la administración de un inhibidor del Factor Xa.Reivindicación 2: La composición farmacéutica según la reivindicación 1, en la que dicho compuesto reactivo ácido se selecciona del grupo que consiste en ácido cítrico, ácido acético, ácido glicólico, ácido láctico, ácido pirúvico, ácido malónico, ácido succínico, ácido glutárico, ácido fumárico, ácido málico, ácido tartárico, ácido ascórbico, ácido maleico, ácido hidroximaleico, ácido benzoico, ácido hidroxibenzoico, ácido fenilacético, ácido cinámico, ácido salicílico, ácido 2-fenoxibenzoico, ácido p-toluenosulfónico, ácido metanosulfónico, ácido 2-hidroxietanosulfónico, ácido hialurónico, ácido acetilsalicílico o aminoácidos o ácidos minerales seleccionados del grupo que consiste en ácido clorhídrico o ácido fosfórico o sales de dichos ácidos orgánicos, aminoácidos y ácidos minerales o una mezcla de uno o más de dichos compuestos reactivos ácidos. Reivindicación 14: La composición farmacéutica según las reivindicaciones 1 a 13, para uso en el tratamiento de infarto de miocardio agudo, infarto de miocardio sin elevación de ST, angina inestable, tromboembolia, oclusión aguda de vasos asociada a la terapia trombolítica, angioplastia coronaria transiuminal percutánea, ataques isquémicos transitorios, infarto cerebral, claudicación intermitente y reestenosis.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11305347 | 2011-03-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR085580A1 true AR085580A1 (es) | 2013-10-09 |
Family
ID=44584895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120101016A AR085580A1 (es) | 2011-03-29 | 2012-03-27 | Formulaciones de otamixaban con estabilidad mejorada |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20140018398A1 (es) |
| EP (1) | EP2691075A1 (es) |
| JP (1) | JP5993933B2 (es) |
| KR (1) | KR101844623B1 (es) |
| CN (1) | CN103561723B (es) |
| AR (1) | AR085580A1 (es) |
| AU (1) | AU2012234323A1 (es) |
| BR (1) | BR112013024801A2 (es) |
| CA (1) | CA2830962C (es) |
| CO (1) | CO6801755A2 (es) |
| EA (1) | EA025572B1 (es) |
| IL (1) | IL228573A (es) |
| MA (1) | MA35050B1 (es) |
| MX (1) | MX342324B (es) |
| SG (1) | SG193932A1 (es) |
| UY (1) | UY33975A (es) |
| WO (1) | WO2012130819A1 (es) |
| ZA (1) | ZA201308061B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101844623B1 (ko) | 2011-03-29 | 2018-04-02 | 사노피 | 안정성이 향상된 오타믹사반 제제 |
| PT3239134T (pt) | 2013-01-31 | 2021-01-28 | Vertex Pharma | Piridona amidas como moduladores dos canais de sódio |
| DE102013212933B3 (de) * | 2013-07-03 | 2014-11-27 | Schaeffler Technologies Gmbh & Co. Kg | Lageranordnung in einem Elektromotor |
| JP7232815B2 (ja) | 2017-08-16 | 2023-03-03 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | ５，１０－メチレン－（６ｒ）－テトラヒドロ葉酸を含む安定な凍結乾燥物 |
| CN109010273B (zh) * | 2018-10-08 | 2021-03-19 | 中国药科大学 | 一种阿哌沙班纳米混悬剂及其制备方法 |
| CN113384526A (zh) * | 2021-08-03 | 2021-09-14 | 合肥医工医药股份有限公司 | 一种稳定的阿哌沙班口服溶液制剂及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3030272A (en) * | 1960-05-26 | 1962-04-17 | Abbott Lab | Stable heaparin solution |
| CA2149150C (en) | 1992-11-27 | 2000-08-01 | David R. Carver | Injectable taxol composition with improved stability |
| US6080767A (en) | 1996-01-02 | 2000-06-27 | Aventis Pharmaceuticals Products Inc. | Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides |
| SI0906094T1 (en) | 1996-01-02 | 2003-12-31 | Aventis Pharmaceuticals Inc. | Substituted n- (aminoiminomethyl or aminomethyl)phenyl)propyl amides |
| GB0108903D0 (en) * | 2000-10-05 | 2001-05-30 | Aventis Pharm Prod Inc | Novel crystalline forms of a factor Xa inhibitor |
| US20050059719A1 (en) * | 2003-09-16 | 2005-03-17 | Badawy Sherif Ibrahim Farag | Solid dosage formulation containing a Factor Xa inhibitor and method |
| FR2863891B1 (fr) * | 2003-12-23 | 2006-03-24 | Pf Medicament | Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation |
| CA2766533A1 (en) * | 2009-07-29 | 2011-02-03 | Sanofi | Otamixaban for treatment of elderly and renal impaired non-st elevation myocardial infarction patients |
| SG193612A1 (en) | 2011-03-29 | 2013-11-29 | Sanofi Sa | Benzoic acid salt of otamixaban |
| KR101844623B1 (ko) | 2011-03-29 | 2018-04-02 | 사노피 | 안정성이 향상된 오타믹사반 제제 |
-
2012
- 2012-03-27 KR KR1020137028419A patent/KR101844623B1/ko active IP Right Grant
- 2012-03-27 MA MA36345A patent/MA35050B1/fr unknown
- 2012-03-27 WO PCT/EP2012/055361 patent/WO2012130819A1/en active Application Filing
- 2012-03-27 US US14/008,343 patent/US20140018398A1/en not_active Abandoned
- 2012-03-27 SG SG2013071352A patent/SG193932A1/en unknown
- 2012-03-27 UY UY0001033975A patent/UY33975A/es not_active Application Discontinuation
- 2012-03-27 CA CA2830962A patent/CA2830962C/en not_active Expired - Fee Related
- 2012-03-27 US US13/431,571 patent/US20120252852A1/en not_active Abandoned
- 2012-03-27 JP JP2014501567A patent/JP5993933B2/ja not_active Expired - Fee Related
- 2012-03-27 AR ARP120101016A patent/AR085580A1/es unknown
- 2012-03-27 AU AU2012234323A patent/AU2012234323A1/en not_active Abandoned
- 2012-03-27 BR BR112013024801A patent/BR112013024801A2/pt not_active Application Discontinuation
- 2012-03-27 EP EP12710516.1A patent/EP2691075A1/en not_active Withdrawn
- 2012-03-27 MX MX2013011260A patent/MX342324B/es active IP Right Grant
- 2012-03-27 EA EA201391406A patent/EA025572B1/ru not_active IP Right Cessation
- 2012-03-27 CN CN201280026572.6A patent/CN103561723B/zh not_active Expired - Fee Related
-
2013
- 2013-09-29 IL IL228573A patent/IL228573A/en active IP Right Grant
- 2013-10-23 CO CO13251310A patent/CO6801755A2/es unknown
- 2013-10-29 ZA ZA2013/08061A patent/ZA201308061B/en unknown
-
2016
- 2016-09-14 US US15/265,191 patent/US9993464B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EA025572B1 (ru) | 2017-01-30 |
| JP5993933B2 (ja) | 2016-09-14 |
| SG193932A1 (en) | 2013-11-29 |
| ZA201308061B (en) | 2015-01-28 |
| IL228573A0 (en) | 2013-12-31 |
| MX342324B (es) | 2016-09-23 |
| KR20140019818A (ko) | 2014-02-17 |
| US20140018398A1 (en) | 2014-01-16 |
| CN103561723B (zh) | 2016-04-20 |
| CN103561723A (zh) | 2014-02-05 |
| CA2830962C (en) | 2019-06-18 |
| BR112013024801A2 (pt) | 2016-12-20 |
| US9993464B2 (en) | 2018-06-12 |
| AU2012234323A1 (en) | 2013-10-17 |
| MA35050B1 (fr) | 2014-04-03 |
| MX2013011260A (es) | 2014-03-27 |
| IL228573A (en) | 2017-12-31 |
| NZ616180A (en) | 2015-10-30 |
| WO2012130819A1 (en) | 2012-10-04 |
| KR101844623B1 (ko) | 2018-04-02 |
| CO6801755A2 (es) | 2013-11-29 |
| EP2691075A1 (en) | 2014-02-05 |
| US20170224668A1 (en) | 2017-08-10 |
| JP2014509621A (ja) | 2014-04-21 |
| US20120252852A1 (en) | 2012-10-04 |
| EA201391406A1 (ru) | 2014-02-28 |
| UY33975A (es) | 2012-10-31 |
| CA2830962A1 (en) | 2012-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR085580A1 (es) | Formulaciones de otamixaban con estabilidad mejorada | |
| DOP2020000062A (es) | Procedimiento para la preparación de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificación para el uso como principio activo farmacéutico | |
| JP2014509621A5 (es) | ||
| AR085668A1 (es) | Terapias combinadas para malignidades hematologicas | |
| HRP20150704T1 (hr) | Derivati piperidinona kao mdm2-inhibitori za lijeäśenje raka | |
| PE20160194A1 (es) | Composiciones y metodos para tratar anemia | |
| CL2013002737A1 (es) | Acido 4-((4-((((1r, 2s)-2-fenilciclopropil)amino)metil)piperidin-1-il)metil)benzoico con actividad inhibidora de desmetilasa 1 especifica de lisina (lsd1); composicion farmaceutica que lo comprende, utiles en el tratamiento del cancer. | |
| MA32368B1 (fr) | Derives d'acide cyclopentanecarboxylique condensé acylamino-substitues et leur utilisation en tant qu'agents pharmaceutiques | |
| CO6382125A2 (es) | Inhibidores de proteína quinasa | |
| PE20091972A1 (es) | Compuestos heterociclicos como inhibidores del factor ixa | |
| NZ603364A (en) | Inhibitors of arginase and their therapeutic applications | |
| PH12017500111A1 (en) | Heterocyclic carboxylic acids as activators of soluble guanylate cyclase | |
| NI201000175A (es) | 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas. | |
| AR088195A1 (es) | Composiciones farmaceuticas de n-metil-2-[3-(e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]-benzamida | |
| PE20081341A1 (es) | Inhibidores de la actividad de la akt | |
| CO6270285A2 (es) | Derivados de 4-[(4-amino-1, 3, 5-triazin-2-il)amino]-n-arilmetilcicloalquilcarboxamida | |
| PE20091486A1 (es) | Derivado de pirrolopirimidina como inhibidor de la enzima pi3k | |
| WO2012006516A3 (en) | Protein kinase c activators and anticoagulant for the treatment of stroke | |
| ECSP13012494A (es) | Inhibidores de oxadiazol de la producción de leucotrieno. | |
| BR112022009185A2 (pt) | Heteroarilaminossulfonamidas de 5 membros para tratar afecções mediadas por atividade de cftr deficiente | |
| MD4557B1 (ro) | Procedeu de obţinere a rivaroxabanului şi un compus intermediar utilizat în acest procedeu | |
| ECSP13012847A (es) | Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparación. | |
| SG179031A1 (en) | Hsl inhibitors useful in the treatment of diabetes | |
| BR112016017985A2 (pt) | Composição farmacêutica para administração tópica e usos da mesma na fabricação de medicamentos | |
| PA8816101A1 (es) | Clorotiofeno - amidas como inhibidores de los factores de coagulacion xa y trombina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |